BioHarvest Sciences Inc. reported preliminary Q3 2025 financial results, showing unaudited revenue of $9.1 million, up from $6.5 million in Q3 2024, a 40% year‑over‑year increase. Adjusted EBITDA loss narrowed to between $0.7 million and $0.4 million, compared with a $2.1 million loss in the same period last year, reflecting improved gross margins and higher sales volume.
Cash and cash equivalents stood at $11 million as of September 30, 2025, providing a solid liquidity buffer amid ongoing investments in manufacturing scale.
For Q4 2025, the company guided revenue of $9 million to $9.5 million and an adjusted EBITDA range of a $0.6 million loss to breakeven, indicating a trajectory toward profitability driven by expanding the VINIA direct‑to‑consumer line and accelerating its CDMO services.
The company also announced a strategic partnership with Saffron Tech, a year‑round saffron cultivator that uses controlled‑environment technology to produce multiple harvests annually. Under the agreement, Saffron Tech will own 75 % of the developed saffron compositions and related intellectual property, while BioHarvest retains 25 %. The partnership will leverage BioHarvest’s Botanical Synthesis platform to produce saffron‑derived compounds at scale, creating a high‑margin product line that complements the company’s dual‑growth engine strategy.
Saffron’s high market value and labor‑intensive cultivation make it an attractive target for BioHarvest’s scalable production method. The collaboration is expected to open a new revenue stream and enhance margin potential, while reinforcing BioHarvest’s position in the premium botanical market.
Management highlighted that the Q3 revenue growth was driven by increased demand for VINIA® capsules and new product launches, and that the narrowing EBITDA loss results from higher manufacturing efficiency and cost controls. The company remains focused on achieving EBITDA breakeven in Q4 2025 and expanding its CDMO services to additional clients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.